Physician profile
Hector Bird
NPI 1033592902
$2,170.81
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.77 · 2021: $707 · 2022: $657 · 2023: $744 · 2024: $14.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $378.77 | 2021-2023 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $285.25 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $240.12 | 2021-2023 | Mounjaro |
| Nevro Corp. | $190.07 | 2023 | Senza |
| Novo Nordisk INC | $182.46 | 2021-2022 | |
| Mannkind Corporation | $159.14 | 2022 | |
| Atricure, INC. | $148.80 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $130.81 | 2023 | Austedo |
| Boston Scientific Corporation | $116.86 | 2022 | |
| Philips North America LLC | $69.65 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.77 | 2020 | |
| Grt US Holding, INC. | $48.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.33 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $34.62 | 2022-2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.14 | 2023 | Xifaxan, Trulance |
| Abbott Laboratories | $15.03 | 2022 | |
| Genentech USA, INC. | $10.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.